Will enhance the performance of a range of therapeutic products
BioOutsource, a contract testing organisation (CTO) based in Glasgow, Scotland, has augmented its position in antibody drug conjugates (ADC) characterisation through a partnership with UK biotechnology company Glythera, a developer of next-generation biotherapeutics through the application of its proprietary linker and stable glycan technologies.
'Building on our position as a leader in biological characterisation of monoclonal antibodies, ADC’s represent an exciting development which will enhance the performance of a wide range of therapeutic products,' said Daniel Galbraith, CSO at BioOutsource.
David Simpson, COO at Glythera said ADC characterisation is an area where the company's linker technologies 'offer significant benefits'.
'This partnership demonstrates recognition of these powerful capabilities and we look forward to working with BioOutsource on this exciting project,' he said.